Skip to main content

Sciona Relocates from UK to Colorado, Hires New CEO

NEW YORK, Jan. 25 (GenomeWeb News) - Sciona, a privately held firm developing DNA screens for nutrigenomics applications, has moved its headquarters from Havant, UK, to Boulder, Colo., the company said today.

 

Sciona has also appointed a new CEO, James Bruce, who most recently served as president and CEO of Madaus, a nutraceutical company.

 

The company's former CEO, Chris Martin, is now chairman of the board. He will continue to reside in the UK.

 

Sciona said it will employ a dozen people in Boulder and additional staff elsewhere in the UK, Italy, and the US, including an R&D lab on the YaleUniversity campus. Several of Sciona's UK employees will relocate to Boulder, including CTO Rosalynn Gill-Garrison, who will lead R&D activities.

 

Sciona currently markets the Cellf genetic screen, which provides nutritional guidelines for consumers based on their genetic profiles. The company also sells genetic screens in the areas of heart health, bone health, antioxidants and detoxification, immune response, and insulin sensitivity.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.